Mechanisms of resistance to RAF inhibitors in melanoma

J Invest Dermatol. 2011 Sep;131(9):1817-20. doi: 10.1038/jid.2011.147. Epub 2011 May 19.


The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Resistance, Neoplasm / physiology*
  • Humans
  • Indoles / therapeutic use*
  • Melanoma / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Sulfonamides / therapeutic use*
  • Vemurafenib
  • raf Kinases / antagonists & inhibitors*


  • Indoles
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Vemurafenib
  • raf Kinases